807 related articles for article (PubMed ID: 26577528)
1. PDL1 Regulation by p53 via miR-34.
Cortez MA; Ivan C; Valdecanas D; Wang X; Peltier HJ; Ye Y; Araujo L; Carbone DP; Shilo K; Giri DK; Kelnar K; Martin D; Komaki R; Gomez DR; Krishnan S; Calin GA; Bader AG; Welsh JW
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26577528
[TBL] [Abstract][Full Text] [Related]
2. Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo.
Li J; Zhong X; Zhao Y; Shen J; Xiao Z; Pilapong C
Sci Rep; 2024 Jan; 14(1):2348. PubMed ID: 38287075
[TBL] [Abstract][Full Text] [Related]
3. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
4. CircKRT1 drives tumor progression and immune evasion in oral squamous cell carcinoma by sponging miR-495-3p to regulate PDL1 expression.
Yang Z; Chen W; Wang Y; Qin M; Ji Y
Cell Biol Int; 2021 Jul; 45(7):1423-1435. PubMed ID: 33675276
[TBL] [Abstract][Full Text] [Related]
5. miR-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis.
Wang DT; Ma ZL; Li YL; Wang YQ; Zhao BT; Wei JL; Qi X; Zhao XT; Jin YX
Oncol Rep; 2013 Jul; 30(1):492-8. PubMed ID: 23670238
[TBL] [Abstract][Full Text] [Related]
6. P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma.
Costa C; Indovina P; Mattioli E; Forte IM; Iannuzzi CA; Luzzi L; Bellan C; De Summa S; Bucci E; Di Marzo D; De Feo M; Mutti L; Pentimalli F; Giordano A
Cell Death Dis; 2020 Sep; 11(9):748. PubMed ID: 32929059
[TBL] [Abstract][Full Text] [Related]
7. circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma.
Wang J; Zhao X; Wang Y; Ren F; Sun D; Yan Y; Kong X; Bu J; Liu M; Xu S
Cell Death Dis; 2020 Jan; 11(1):32. PubMed ID: 31949130
[TBL] [Abstract][Full Text] [Related]
8. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.
Kang J; Kim E; Kim W; Seong KM; Youn H; Kim JW; Kim J; Youn B
J Biol Chem; 2013 Sep; 288(38):27343-27357. PubMed ID: 23902763
[TBL] [Abstract][Full Text] [Related]
9. Characterization of miR-34a-Induced Epithelial-Mesenchymal Transition in Non-Small Lung Cancer Cells Focusing on p53.
Kawami M; Takenaka S; Akai M; Yumoto R; Takano M
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944497
[TBL] [Abstract][Full Text] [Related]
10. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
11. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer.
Ye M; Zhang J; Zhang J; Miao Q; Yao L; Zhang J
Cancer Lett; 2015 Feb; 357(1):196-205. PubMed ID: 25444916
[TBL] [Abstract][Full Text] [Related]
12. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.
Huang X; Xie X; Wang H; Xiao X; Yang L; Tian Z; Guo X; Zhang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 Sep; 36(1):129. PubMed ID: 28915924
[TBL] [Abstract][Full Text] [Related]
13. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
14. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression and clinical outcome of small cell lung cancer.
Lee JH; Voortman J; Dingemans AM; Voeller DM; Pham T; Wang Y; Giaccone G
PLoS One; 2011; 6(6):e21300. PubMed ID: 21731696
[TBL] [Abstract][Full Text] [Related]
16. miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis.
Song C; Lu P; Sun G; Yang L; Wang Z; Wang Z
Biochem Biophys Res Commun; 2017 Jan; 482(1):22-27. PubMed ID: 27836543
[TBL] [Abstract][Full Text] [Related]
17. MiR-34a suppresses the proliferation and invasion of gastric cancer by modulating PDL1 in the immune microenvironment.
Yong H; Fu J; Gao G; Shi H; Zheng D; Zhou X
Mol Cell Probes; 2020 Oct; 53():101601. PubMed ID: 32445780
[TBL] [Abstract][Full Text] [Related]
18. Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process.
Li F; Zhu T; Yue Y; Zhu X; Wang J; Liang L
Oncol Rep; 2018 Aug; 40(2):775-782. PubMed ID: 29901173
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
